YL202 + furmonertinib

YL202 + furmonertinib is an investigational combination therapy under clinical evaluation, composed of the antibody-drug conjugate YL202 and the small molecule tyrosine kinase inhibitor furmonertinib. YL202 is an antibody-drug conjugate designed for targeted anti-tumor therapy, although its precise target and mechanism remain undisclosed in public trial registries. Furmonertinib is a third-generation, highly brain-penetrant, irreversible inhibitor of mutant Epidermal Growth Factor Receptor (EGFR), particularly active against common and uncommon EGFR mutations in non-small cell lung cancer (NSCLC), including T790M and exon 20 insertions. The combination is being tested in advanced solid tumors, including NSCLC and breast cancer, in phase Ib/II clinical trials to evaluate safety, tolerability, and preliminary antitumor efficacy[1][3].

Other names

YL202 + furmonertinibfurmonertinib mesilateAST2818AST-2818AST 2818alflutinib